Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA appropriations bill passes House

This article was originally published in The Tan Sheet

Executive Summary

The House on Aug. 2 passed its appropriations bill, H.R. 3161, that includes FDA funding, which proposes $1.69 bil. in direct funding for the agency. No significant changes affecting FDA were made from the bill sent top the floor by the Agriculture Appropriations Subcommittee (1"The Tan Sheet" July 23, 2007, p. 4). The same day, Sen. Mike Enzi, R-Wyo., asked Majority Leader Harry Reid, D-Nev., to delay naming conferees for the legislation. "If we do this too early, we set ourselves up for the blame game, not for getting this key legislation done," Enzi said. The Senate has not yet passed its corresponding bill, S. 1859...

You may also be interested in...



Appropriators Boost FDA Budget For Food Safety While Opposing Lab Closings

House and Senate appropriators make it known in reports on FDA's fiscal 2008 appropriation that they question the agency's plan to close more than half of its field labs, with the House bill specifically banning funding for the reorganization

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel